Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.
Online First
Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.
Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.
Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections. You may also view the abstract by clicking on the article link.
Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.
Editor’s Letter
Extrapolation requires reading between the lines / Professor Philip D Walson, MD, USA
Original Research
Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars / Michael S Reilly, Esq, USA; Jane Barratt, PhD, Canada
Review Article
Statistical tests for detecting reference product change in biosimilar studies / Jiayin Zheng1, PhD; Peijin Wang2, MS; Yixin Wang3, PhD; Shein-Chung Chow2, PhD, USA
The incorporation of the Halal Management System (HMS) by the pharmaceutical industry / Ka-Liong Tan1, DPhil; Ainoon Othman1; Irwan Mohd Subri3; Noor Fadzilah Zulkifli1; Mohd Mahyeddin Mohd Salleh3; Nazariyah Yahaya4; Khairun Nain Nor Aripin1; Shahirah Nadiah Shaharuddin5; Seri Azalina Mohd Ghazalli6;Muhammad Syazan Sulaiman6, Malaysia
Perspective
Ethnic sensitivity assessments in biosimilar monoclonal antibodies clinical development programmes: necessary or not? / Sandeep N Athalye1, MBBS, MD; Dev B Baruah1, MPharm; Shivani Mittra1, MPharm, PhD; Ankit Ranpura1, MD; Kuldeep Kumar1, PhD; Elena Wolff-Holz2, MD
Special Report
Follow-on biologicals/biosimilars approved in Brazil: May 2023 update / Sílvia Helena Cestari de Oliveira, MSc, Brazil
Meeting Report
Medicare drug price negotiations: impact on healthcare development and patient access to medicines / Michael S Reilly, Esq; Thomas R Barker, Esq, JD; Charles M Clapton, Steven J Potts, PhD, MBA; Andrew Spiegel, Esq USA/Canada
Regulatory
Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD, Iran
Sponsored Article
Biosimilar antibody drug conjugates: considerations of higher order structure and aggregation / Easton RL, BSC (Hons), DIC, PhD, UK
Click here for more details on the educational series.
Contact us for an updated list of editorial topics in forthcoming issues.
*Editorial content may differ from final version of manuscript published in print.